KALA
What one share of Kala Bio holds
Pharmaceutical Preparations
We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. Our current focus is leveraging our mesenchymal stem cell secretome (“MSC-S”) platform to test development of a scalable AI platform-as-a-service business to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments.
Kala Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.30 |
|---|---|
| Cash and investments | $0.01 |
| Debt | $1.39 |
| Book value | $0.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$1,404 | $6.48 | −$1,164 | — | −$3,714 |
| 2017 | $0.00 | −$185.54 | $2.11 | −$151.99 | — | — |
| 2018 | — | −$124.73 | $2.95 | −$104.10 | — | $155.00 |
| 2019 | $8.88 | −$137.89 | $1.95 | −$137.47 | — | $41.14 |
| 2020 | $6.07 | −$99.59 | — | −$86.58 | — | $84.86 |
| 2021 | $426.89 | −$5,416 | — | −$4,111 | — | $635.33 |
| 2022 | $127.97 | −$1,474 | — | −$2,595 | — | $555.78 |
| 2023 | $0.00 | −$867.58 | — | −$574.16 | — | $135.97 |
| 2024 | $0.00 | −$507.25 | — | −$387.01 | — | $101.23 |
| 2025 | $0.00 | −$165.56 | — | −$196.31 | — | $12.56 |